Cantabio Pharmaceuticals, Inc. (CTBO)
- Previous Close
1.0100 - Open
1.0100 - Bid --
- Ask --
- Day's Range
1.0100 - 1.0100 - 52 Week Range
1.0100 - 1.0100 - Volume
24 - Avg. Volume
0 - Market Cap (intraday)
563,600 - Beta (5Y Monthly) 0.13
- PE Ratio (TTM)
-- - EPS (TTM)
-8.0800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.
www.cantabio.comRelated News
Performance Overview: CTBO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTBO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTBO
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.11
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-470.97%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.54M
Diluted EPS (ttm)
-8.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
283.37k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-217.4k
Company Insights: CTBO
CTBO does not have Company Insights